STRUCTURE · MATCHED
TB-500 Mechanism of Action: Actin Sequestration and the LKKTETQ Motif
The one part of the story the fragment demonstrably carries — the WH2-type actin-binding motif of thymosin beta-4, resolved by crystallography to a 1:1 monomer complex.
The motif: residues 17-23 of thymosin beta-4
The TB-500 mechanism of action begins with one sequence: Ac-LKKTETQ, residues 17–23 of thymosin beta-4 [1]. This is the conserved actin-binding region of the beta-thymosins — a WH2-type (Wiskott-Aldrich syndrome protein Homology 2) actin-binding motif, the structural class shared by monomer-sequestering and filament-assembly proteins across the cytoskeleton.
Full-length thymosin beta-4 is the body's major intracellular G-actin sequestering peptide. It binds monomeric (globular) actin and holds a buffered reserve of unpolymerized actin, regulating how much monomer is available to build filaments [2]. That buffering controls cytoskeletal assembly, and therefore cell motility — the upstream lever beneath migration, wound closure and angiogenesis.
TB-500 is the synthetic 7-mer carrying that motif. The mechanistic question this whole site reconciles is narrow and specific: the fragment carries the actin-binding sequence, but most downstream effects in the literature were measured on the intact protein.
How does TB-500 work?
Its LKKTETQ motif is the actin-binding region of thymosin beta-4, which binds monomeric G-actin in a 1:1 complex to buffer the unpolymerized actin pool and regulate cytoskeletal dynamics, cell migration and motility [1][2]. X-ray crystallography of a gelsolin-domain-1–Tβ4–actin hybrid, resolved at 2 Å, showed the protein sequesters the monomer by capping both of its ends, preventing it from joining a filament [1].
A review framed thymosin beta-4 as an actin-sequestering protein that "moonlights" to repair injured tissues, integrating the cytoskeletal and regenerative roles into one model [4]. Whether the isolated 7-mer reproduces those downstream repair functions at peptide-research doses is not established in controlled human trials [10].
What is the relationship between TB-500 and Thymosin Beta-4?
TB-500 is a 7-amino-acid fragment — residues 17–23, the actin-binding motif — of the full 43-residue thymosin beta-4 protein [1][5]. Most efficacy research uses the full-length protein, not the fragment. The parent (gene TMSB4X, UniProt P62328) is ~4963 Da; the fragment is ~889 Da [5]. The fragment carries the actin-binding sequence but not the N-terminal region that yields Ac-SDKP, so it is structurally a subset of the parent, not an equivalent.
What is the amino acid sequence of TB-500?
Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (Ac-LKKTETQ): an N-terminally acetylated heptapeptide with molecular weight ~889 Da and formula C38H68N10O14, corresponding to the WH2-type actin-binding region of thymosin beta-4 [1]. The acetyl cap sits on the leucine N-terminus; the seven residues run leucine, lysine, lysine, threonine, glutamate, threonine, glutamine.
What is the difference between TB-500 and full-length Thymosin Beta-4?
TB-500 is only the ~889 Da Ac-LKKTETQ actin-binding fragment; full-length Tβ4 is the ~4963 Da intact protein [1][5]. The fragment does not generate Ac-SDKP, the N-terminal cleavage product with its own anti-fibrotic and angiogenic activity [5]. Its human efficacy is not established in controlled trials, whereas the parent protein has reached Phase 1 in humans [10]. Functionally, the protein carries effects the 7-mer has not been shown to match.
Does a fragment carry the protein's repair activity?
Partly, and this is the most directly relevant evidence. A synthetic peptide containing thymosin beta-4's actin-binding domain reproduced aspects of the protein's wound-healing activity in db/db diabetic and aged mice [3]. That finding is the bridge between the structural motif TB-500 carries and the repair functions attributed to the parent protein — a synthetic actin-binding-domain peptide retained wound-healing-relevant activity.
But "aspects" is the operative word. The fragment is not the protein, the model was not human, and reproducing a slice of activity in mice is not the same as matching the full regenerative profile reported for Tβ4. The cytoskeletal lattice the protein regulates — a structured weave of actin monomers with a sequestered free-monomer pool — is the same machinery either molecule acts on, but the magnitude and breadth of effect for the isolated 7-mer in humans remains the open line.